Vitamin D3 for Life

Live Enlightened

Physiology

Liver Disease, Carrier Proteins and Vitamin D Availability: Study Summary

Previous related pageLiver Disease, Carrier Proteins and Vitamin D Availability: Full StudyNext related pageLiver Disease, Carrier Proteins and Vitamin D Availability: Full Study
Study at a glance

How might different liver diseases affect vitamin D?

This page summarises studies of vitamin D in different liver conditions. Tissue samples, blood tests and treatment trials answer different questions. The findings in inflammatory fatty liver disease and hepatitis C did not establish that all liver disease causes a general loss of vitamin D conversion. They also did not show whether the tissue changes came before or after the illness.

What did vitamin D blood studies in cirrhosis find?

Most vitamin D blood tests measure a total amount that includes vitamin D attached to proteins and vitamin D that is unbound. In one cirrhosis study, people with less albumin, a blood protein, had lower total and unbound amounts. The unbound share of the total was higher, but that did not mean more unbound vitamin D was available. A separate study comparing people with and without cirrhosis found higher unbound levels in the cirrhosis group. These were different comparisons using different methods.

Did supplements improve liver disease?

A study following people with cirrhosis found a link between low vitamin D and death, but the link was uncertain after accounting for other factors. A trial in fatty liver disease raised vitamin D blood levels without demonstrating improvement in liver fat measured by scanning. This result applies to the people and treatment studied; it does not show that every possible treatment has no effect.

Can one vitamin D result guide treatment for everyone with liver disease?

Calculations and direct measurements of unbound vitamin D can disagree. Neither automatically measures delivery to every tissue. A low total result alone cannot prove harm, harmlessness or a benefit from treatment. These studies do not establish one vitamin D blood target for all people with liver disease or show that supplements treat the underlying liver condition.

Read the full article below ↓

Vitamin D measurements can be harder to interpret in liver disease because tissue changes and circulating carrier proteins may affect different parts of the pathway. Fatty liver disease, viral hepatitis and cirrhosis should therefore remain separate when their evidence is compared. For the detailed methods and findings, see Liver Disease, Carrier Proteins and Vitamin D Availability: Full Study.

What is the central question?

The question is what a vitamin D result means in the particular liver condition being studied. A biopsy examines sampled tissue, a blood test measures circulating material and a treatment trial tests an intervention. Their results become misleading if those different jobs are merged. The wider background is Vitamin D and Liver Function.

What did liver biopsies show?

Barchetta’s biopsy study included nonalcoholic steatohepatitis (NASH), a form of fatty liver disease with inflammatory injury, and chronic hepatitis C. It found disease-specific patterns of vitamin D-related protein staining. The NASH findings did not establish a general loss of vitamin D conversion enzymes. The hepatitis C observations differed, and neither comparison established which changes came first or demonstrated a supplementation benefit.

Why do carrier proteins matter?

A total result includes protein-bound and unbound 25-hydroxyvitamin D, abbreviated 25(OH)D. The free concentration measures the unbound amount, while the free percentage describes its share of the total. These are not interchangeable. The carrier background is explained in Vitamin D Binding Protein Explained.

In Lai’s cirrhosis study, lower albumin accompanied lower total vitamin D, lower absolute free vitamin D and a higher free percentage. The higher percentage therefore did not mean that the absolute unbound amount was preserved.

For an illustrative comparison, a smaller cake can have a larger percentage allocated to one slice while that slice still weighs less. The relevant scientific task is to identify which quantity was measured. The study also examined regulatory and bone-turnover markers, which cannot replace measured fractures or bone density.

Does measuring free vitamin D solve the problem?

Schwartz’s measurement study found disagreement between calculated and directly measured free vitamin D. Calculation depends on assumptions and input measurements; direct assays also require validation. Neither result should be treated automatically as a complete measurement of tissue availability. The related distinctions are developed in the Full Study of free, albumin-bound and total vitamin D in blood.

Schwartz also found higher absolute free levels in cirrhosis than in its comparison group. Unlike Lai’s analysis, this compared cirrhosis with people without cirrhosis. Different comparison groups and methods prevent a single universal rule about free levels.

Do low levels prove that treatment improves liver disease?

No. Paternostro’s cirrhosis cohort found an unadjusted mortality association, but its adjusted vitamin D estimate remained uncertain. Observing a marker alongside more severe disease cannot show that changing the marker will change the outcome.

In Barchetta’s randomized fatty-liver trial, vitamin D supplementation increased circulating 25(OH)D without demonstrating improvement in the primary MRI liver-fat endpoint. That finding concerns the tested population and regimen; it is not proof that every possible intervention has no effect.

What is the main conclusion?

Liver disease changes the context in which vitamin D is interpreted. The condition, disease severity, carrier proteins, assay and outcome all matter. None of these studies establishes one blood target for every liver patient, proves that a low total result is harmless or shows that supplementation treats the underlying liver condition. Their value is in explaining why a single number cannot answer all those questions.

Scientific sources

Barchetta I et al. Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. Hepatology. 2012;56(6):2180 to 2187. DOI: 10.1002/hep.25930.

Lai JC et al. Total 25(OH) vitamin D, free 25(OH) vitamin D and markers of bone turnover in cirrhotics with and without synthetic dysfunction. Liver International. 2015;35(10):2294 to 2300. DOI: 10.1111/liv.12819.

Schwartz JB et al. A comparison of measured and calculated free 25(OH) vitamin D levels in clinical populations. Journal of Clinical Endocrinology & Metabolism. 2014;99(5):1631 to 1637. DOI: 10.1210/jc.2013-3874.

Paternostro R et al. Low 25-OH-vitamin D levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis. Wiener klinische Wochenschrift. 2017;129:8 to 15. DOI: 10.1007/s00508-016-1127-1.

Barchetta I et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Medicine. 2016;14:92. DOI: 10.1186/s12916-016-0638-y.

Related reading

Original sources

Source

Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus

Published in Hepatology (2012).

Publication details

Barchetta I et al. Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. Hepatology. 2012;56(6):2180 to 2187. DOI: 10.1002/hep.25930.

Read more →